Literature DB >> 25562616

Prevention and reversal of lipotoxicity-induced hepatic insulin resistance and steatohepatitis in mice by an antioxidant carotenoid, β-cryptoxanthin.

Yinhua Ni1, Mayumi Nagashimada, Lili Zhan, Naoto Nagata, Masuko Kobori, Minoru Sugiura, Kazunori Ogawa, Shuichi Kaneko, Tsuguhito Ota.   

Abstract

Excessive hepatic lipid accumulation promotes macrophages/Kupffer cells activation, resulting in exacerbation of insulin resistance and progression of nonalcoholic steatohepatitis (NASH). However, few promising treatment modalities target lipotoxicity-mediated hepatic activation/polarization of macrophages for NASH. Recent epidemiological surveys showed that serum β-cryptoxanthin, an antioxidant carotenoid, was inversely associated with the risks of insulin resistance and liver dysfunction. In the present study, we first showed that β-cryptoxanthin administration ameliorated hepatic steatosis in high-fat diet-induced obese mice. Next, we investigated the preventative and therapeutic effects of β-cryptoxanthin using a lipotoxic model of NASH: mice fed a high-cholesterol and high-fat (CL) diet. After 12 weeks of CL diet feeding, β-cryptoxanthin administration attenuated insulin resistance and excessive hepatic lipid accumulation and peroxidation, with increases in M1-type macrophages/Kupffer cells and activated stellate cells, and fibrosis in CL diet-induced NASH. Comprehensive gene expression analysis showed that β-cryptoxanthin down-regulated macrophage activation signal-related genes significantly without affecting most lipid metabolism-related genes in the liver. Importantly, flow cytometry analysis revealed that, on a CL diet, β-cryptoxanthin caused a predominance of M2 over M1 macrophage populations, in addition to reducing total hepatic macrophage and T-cell contents. In parallel, β-cryptoxanthin decreased lipopolysaccharide-induced M1 marker mRNA expression in peritoneal macrophages, whereas it augmented IL-4-induced M2 marker mRNA expression, in a dose-dependent manner. Moreover, β-cryptoxanthin reversed steatosis, inflammation, and fibrosis progression in preexisting NASH in mice. In conclusion, β-cryptoxanthin prevents and reverses insulin resistance and steatohepatitis, at least in part, through an M2-dominant shift in macrophages/Kupffer cells in a lipotoxic model of NASH.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25562616     DOI: 10.1210/en.2014-1776

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  29 in total

Review 1.  Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Authors:  Xiaohan Xu; Kyle L Poulsen; Lijuan Wu; Shan Liu; Tatsunori Miyata; Qiaoling Song; Qingda Wei; Chenyang Zhao; Chunhua Lin; Jinbo Yang
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

Review 2.  An Update on the Chemokine System in the Development of NAFLD.

Authors:  Naoto Nagata; Guanliang Chen; Liang Xu; Hitoshi Ando
Journal:  Medicina (Kaunas)       Date:  2022-06-05       Impact factor: 2.948

3.  Macrophages in Nonalcoholic Steatohepatitis: Friend or Foe?

Authors:  Joel Grunhut; Wei Wang; Berk Aykut; Inderdeep Gakhal; Alejandro Torres-Hernandez; George Miller
Journal:  Eur Med J Hepatol       Date:  2018-05-31

Review 4.  Roles of Chemokines and Chemokine Receptors in Obesity-Associated Insulin Resistance and Nonalcoholic Fatty Liver Disease.

Authors:  Liang Xu; Hironori Kitade; Yinhua Ni; Tsuguhito Ota
Journal:  Biomolecules       Date:  2015-07-21

5.  High-serum carotenoids associated with lower risk for developing type 2 diabetes among Japanese subjects: Mikkabi cohort study.

Authors:  Minoru Sugiura; Mieko Nakamura; Kazunori Ogawa; Yoshinori Ikoma; Masamichi Yano
Journal:  BMJ Open Diabetes Res Care       Date:  2015-12-01

Review 6.  Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments.

Authors:  Hironori Kitade; Guanliang Chen; Yinhua Ni; Tsuguhito Ota
Journal:  Nutrients       Date:  2017-04-14       Impact factor: 5.717

7.  SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice.

Authors:  Liang Xu; Naoto Nagata; Mayumi Nagashimada; Fen Zhuge; Yinhua Ni; Guanliang Chen; Eric Mayoux; Shuichi Kaneko; Tsuguhito Ota
Journal:  EBioMedicine       Date:  2017-05-26       Impact factor: 8.143

8.  Astaxanthin prevents and reverses diet-induced insulin resistance and steatohepatitis in mice: A comparison with vitamin E.

Authors:  Yinhua Ni; Mayumi Nagashimada; Fen Zhuge; Lili Zhan; Naoto Nagata; Akemi Tsutsui; Yasuni Nakanuma; Shuichi Kaneko; Tsuguhito Ota
Journal:  Sci Rep       Date:  2015-11-25       Impact factor: 4.379

Review 9.  Novel Action of Carotenoids on Non-Alcoholic Fatty Liver Disease: Macrophage Polarization and Liver Homeostasis.

Authors:  Yinhua Ni; Fen Zhuge; Mayumi Nagashimada; Tsuguhito Ota
Journal:  Nutrients       Date:  2016-06-24       Impact factor: 5.717

Review 10.  Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease.

Authors:  Guanliang Chen; Yinhua Ni; Naoto Nagata; Liang Xu; Tsuguhito Ota
Journal:  Int J Mol Sci       Date:  2016-08-23       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.